A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population.
According to study findings presented by Glooko at the American Diabetes Association (ADA) scientific sessions on Friday, remote patient monitoring (RPM) helped patients with type 2 diabetes achieve improved and sustained glycaemic control.
The company aims to secure a CE mark for the Tempo Smart Button by the end of this year, enabling it and the Tempo Pen to be sold as a single package in European markets.
Glooko will partner with Eli Lilly for a strategic digital health collaboration using Eli Lilly’s connected insulin pens, the Tempo Pen and Tempo Smart Button.
To make sure its upcoming connected insulin pen system will work with the user’s choice of daily diabetes management platforms, Eli Lilly & Co. has signed compatibility agreements with four international providers. That includes glucose monitoring sensors, digital health programs and other tools from Roche, Dexcom, Glooko and myDiabby Healthcare.
In 2015, the Clinical Trial Transformation Initiative (CTTI) recommended that trial sponsors consider fully or partially decentralized DCTs, defined as trials executed through telemedicine and mobile/local healthcare providers.
As with so many aspects of our daily lives, the impact of the COVID-19 pandemic on clinical trials was both widespread and monumental. Thousands of trials—an estimated 80% of non-COVID-19 trials
COVID-19 has changed the way healthcare is delivered and has rapidly affected the virtual care adoption and usage. To manage better their day-to-day routine care and control their diabetes and other chronic diseases symptoms.
The pandemic has turned lesser-known biopharmaceutical startups into household names, including vaccine developers Moderna and BioNTech. Now the company behind the AstraZeneca COVID-19 vaccine.
Glooko, the maker of a digital platform for managing diabetes and other chronic diseases, announced today a $30 million Series D funding round led by Health Catalyst Capital, Canaan Partners